Chardan Capital Has Negative Outlook of iBio FY2025 Earnings

iBio, Inc. (NYSE:IBIO) – Equities researchers at Chardan Capital reduced their FY2025 EPS estimates for iBio in a research report issued on Monday, May 5th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($1.71) per share for the year, down from their prior forecast of ($1.53). Chardan Capital currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for iBio’s current full-year earnings is ($1.74) per share. Chardan Capital also issued estimates for iBio’s FY2026 earnings at ($0.66) EPS.

Separately, StockNews.com raised iBio to a “sell” rating in a research note on Tuesday, March 18th.

iBio Stock Performance

Shares of iBio stock opened at $0.77 on Thursday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.05. iBio has a 52 week low of $0.64 and a 52 week high of $6.89. The firm has a fifty day moving average of $2.73 and a two-hundred day moving average of $2.86.

Institutional Investors Weigh In On iBio

An institutional investor recently raised its position in iBio stock. Geode Capital Management LLC boosted its stake in shares of iBio, Inc. (NYSE:IBIO) by 52.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 83,797 shares of the company’s stock after buying an additional 28,775 shares during the period. Geode Capital Management LLC owned approximately 0.85% of iBio worth $205,000 as of its most recent filing with the SEC. 7.90% of the stock is currently owned by hedge funds and other institutional investors.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.